Effects of chronic glucagon-like peptide-2 therapy during weaning in neonatal pigs

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Effects of chronic glucagon-like peptide-2 therapy during weaning in neonatal pigs. / Sigalet, David L; de Heuvel, Elaine; Wallace, Laurie; Bulloch, Estrella; Turner, Justine; Wales, Paul W; Nation, Patrick; Wizzard, Pamela R; Hartmann, Bolette; Assad, Meena; Holst, Jens Juul.

I: Regulatory Peptides, Bind 188, 10.01.2014, s. 70-80.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Sigalet, DL, de Heuvel, E, Wallace, L, Bulloch, E, Turner, J, Wales, PW, Nation, P, Wizzard, PR, Hartmann, B, Assad, M & Holst, JJ 2014, 'Effects of chronic glucagon-like peptide-2 therapy during weaning in neonatal pigs', Regulatory Peptides, bind 188, s. 70-80. https://doi.org/10.1016/j.regpep.2013.12.006

APA

Sigalet, D. L., de Heuvel, E., Wallace, L., Bulloch, E., Turner, J., Wales, P. W., ... Holst, J. J. (2014). Effects of chronic glucagon-like peptide-2 therapy during weaning in neonatal pigs. Regulatory Peptides, 188, 70-80. https://doi.org/10.1016/j.regpep.2013.12.006

Vancouver

Sigalet DL, de Heuvel E, Wallace L, Bulloch E, Turner J, Wales PW o.a. Effects of chronic glucagon-like peptide-2 therapy during weaning in neonatal pigs. Regulatory Peptides. 2014 jan 10;188:70-80. https://doi.org/10.1016/j.regpep.2013.12.006

Author

Sigalet, David L ; de Heuvel, Elaine ; Wallace, Laurie ; Bulloch, Estrella ; Turner, Justine ; Wales, Paul W ; Nation, Patrick ; Wizzard, Pamela R ; Hartmann, Bolette ; Assad, Meena ; Holst, Jens Juul. / Effects of chronic glucagon-like peptide-2 therapy during weaning in neonatal pigs. I: Regulatory Peptides. 2014 ; Bind 188. s. 70-80.

Bibtex

@article{ea3385bfa9d548d4b764aef32070e524,
title = "Effects of chronic glucagon-like peptide-2 therapy during weaning in neonatal pigs",
abstract = "BACKGROUND: The enteroendocrine hormone glucagon like peptide-2 (GLP-2) and its ligands are under development as therapeutic agents for a variety of intestinal pathologies. A number of these conditions occur in neonates and infants, and thus a detailed understanding of the effects of GLP-2 during the phase of rapid growth during infancy is required to guide the development of therapeutic applications. We studied the effects of GLP-2 in the neonatal pig to determine the potential effects of exogenous administration.METHODS: Two day old newborn domestic piglets were treated with GLP-2 (1-33) at 40 μg/kg/day or control drug vehicle (saline), by subcutaneous injection, given in two doses per day, (n=6/group) for 42 days. Animals were weaned normally, over days 21-25. In the fifth week of life, they underwent neuro-developmental testing, and a pharmacokinetic study. On day 42, they were euthanized, and a complete necropsy performed, with histological assessment of tissues from all major organs.RESULTS: GLP-2 treatment was well tolerated, one control animal died from unrelated causes. There were no effects of GLP-2 on weight gain, feed intake, or behavior. In the treated animals, GLP-2 levels were significantly elevated at 2400±600 pM while at necropsy, organ weights and histology were not affected except in the intestine, where the villus height in the small intestine and the crypt depth, throughout the small intestine and colon, were increased. Similarly, the rate of crypt cell proliferation (Ki-67 staining) was increased in the GLP-2 treated animals and the rate of apoptosis (Caspase-3) was decreased, the depth of the microvilli was increased and the expression of the mRNA for the GLP-2 receptor was decreased throughout the small and large intestine.CONCLUSIONS: In these growing animals, exogenous GLP-2 at pharmacologic doses was well tolerated, with effects confined to the gastrointestinal tract.",
author = "Sigalet, {David L} and {de Heuvel}, Elaine and Laurie Wallace and Estrella Bulloch and Justine Turner and Wales, {Paul W} and Patrick Nation and Wizzard, {Pamela R} and Bolette Hartmann and Meena Assad and Holst, {Jens Juul}",
note = "Copyright {\circledC} 2013 Elsevier B.V. All rights reserved.",
year = "2014",
month = "1",
day = "10",
doi = "10.1016/j.regpep.2013.12.006",
language = "English",
volume = "188",
pages = "70--80",
journal = "Regulatory Peptides",
issn = "0167-0115",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Effects of chronic glucagon-like peptide-2 therapy during weaning in neonatal pigs

AU - Sigalet, David L

AU - de Heuvel, Elaine

AU - Wallace, Laurie

AU - Bulloch, Estrella

AU - Turner, Justine

AU - Wales, Paul W

AU - Nation, Patrick

AU - Wizzard, Pamela R

AU - Hartmann, Bolette

AU - Assad, Meena

AU - Holst, Jens Juul

N1 - Copyright © 2013 Elsevier B.V. All rights reserved.

PY - 2014/1/10

Y1 - 2014/1/10

N2 - BACKGROUND: The enteroendocrine hormone glucagon like peptide-2 (GLP-2) and its ligands are under development as therapeutic agents for a variety of intestinal pathologies. A number of these conditions occur in neonates and infants, and thus a detailed understanding of the effects of GLP-2 during the phase of rapid growth during infancy is required to guide the development of therapeutic applications. We studied the effects of GLP-2 in the neonatal pig to determine the potential effects of exogenous administration.METHODS: Two day old newborn domestic piglets were treated with GLP-2 (1-33) at 40 μg/kg/day or control drug vehicle (saline), by subcutaneous injection, given in two doses per day, (n=6/group) for 42 days. Animals were weaned normally, over days 21-25. In the fifth week of life, they underwent neuro-developmental testing, and a pharmacokinetic study. On day 42, they were euthanized, and a complete necropsy performed, with histological assessment of tissues from all major organs.RESULTS: GLP-2 treatment was well tolerated, one control animal died from unrelated causes. There were no effects of GLP-2 on weight gain, feed intake, or behavior. In the treated animals, GLP-2 levels were significantly elevated at 2400±600 pM while at necropsy, organ weights and histology were not affected except in the intestine, where the villus height in the small intestine and the crypt depth, throughout the small intestine and colon, were increased. Similarly, the rate of crypt cell proliferation (Ki-67 staining) was increased in the GLP-2 treated animals and the rate of apoptosis (Caspase-3) was decreased, the depth of the microvilli was increased and the expression of the mRNA for the GLP-2 receptor was decreased throughout the small and large intestine.CONCLUSIONS: In these growing animals, exogenous GLP-2 at pharmacologic doses was well tolerated, with effects confined to the gastrointestinal tract.

AB - BACKGROUND: The enteroendocrine hormone glucagon like peptide-2 (GLP-2) and its ligands are under development as therapeutic agents for a variety of intestinal pathologies. A number of these conditions occur in neonates and infants, and thus a detailed understanding of the effects of GLP-2 during the phase of rapid growth during infancy is required to guide the development of therapeutic applications. We studied the effects of GLP-2 in the neonatal pig to determine the potential effects of exogenous administration.METHODS: Two day old newborn domestic piglets were treated with GLP-2 (1-33) at 40 μg/kg/day or control drug vehicle (saline), by subcutaneous injection, given in two doses per day, (n=6/group) for 42 days. Animals were weaned normally, over days 21-25. In the fifth week of life, they underwent neuro-developmental testing, and a pharmacokinetic study. On day 42, they were euthanized, and a complete necropsy performed, with histological assessment of tissues from all major organs.RESULTS: GLP-2 treatment was well tolerated, one control animal died from unrelated causes. There were no effects of GLP-2 on weight gain, feed intake, or behavior. In the treated animals, GLP-2 levels were significantly elevated at 2400±600 pM while at necropsy, organ weights and histology were not affected except in the intestine, where the villus height in the small intestine and the crypt depth, throughout the small intestine and colon, were increased. Similarly, the rate of crypt cell proliferation (Ki-67 staining) was increased in the GLP-2 treated animals and the rate of apoptosis (Caspase-3) was decreased, the depth of the microvilli was increased and the expression of the mRNA for the GLP-2 receptor was decreased throughout the small and large intestine.CONCLUSIONS: In these growing animals, exogenous GLP-2 at pharmacologic doses was well tolerated, with effects confined to the gastrointestinal tract.

U2 - 10.1016/j.regpep.2013.12.006

DO - 10.1016/j.regpep.2013.12.006

M3 - Journal article

C2 - 24368164

VL - 188

SP - 70

EP - 80

JO - Regulatory Peptides

JF - Regulatory Peptides

SN - 0167-0115

ER -

ID: 117852814